MA43088A1 - Anticorps anti-il-17c - Google Patents

Anticorps anti-il-17c

Info

Publication number
MA43088A1
MA43088A1 MA43088A MA43088A MA43088A1 MA 43088 A1 MA43088 A1 MA 43088A1 MA 43088 A MA43088 A MA 43088A MA 43088 A MA43088 A MA 43088A MA 43088 A1 MA43088 A1 MA 43088A1
Authority
MA
Morocco
Prior art keywords
antibodies
relates
antibody fragments
antibody
psoriasis
Prior art date
Application number
MA43088A
Other languages
English (en)
Other versions
MA43088B1 (fr
Inventor
Jan Dominik Haas
Jürgen Klattig
Nick Ernest René Vandeghinste
Original Assignee
Morphosys Ag
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag, Galapagos Nv filed Critical Morphosys Ag
Publication of MA43088A1 publication Critical patent/MA43088A1/fr
Publication of MA43088B1 publication Critical patent/MA43088B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps ou des fragments d'anticorps se liant à l'il-17c humaine. En particulier, l'invention concerne des anticorps ou des fragments d'anticorps qui présentent des propriétés bénéfiques combinées et sont donc utiles pour le traitement d'êtres humains présentant, par exemple, une dermatite atopique ou un psoriasis.
MA43088A 2016-02-19 2017-02-17 Anticorps anti-il-17c MA43088B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16156582 2016-02-19
EP16156651 2016-02-22
PCT/EP2017/053592 WO2017140831A1 (fr) 2016-02-19 2017-02-17 Anticorps anti-il-17c

Publications (2)

Publication Number Publication Date
MA43088A1 true MA43088A1 (fr) 2019-05-31
MA43088B1 MA43088B1 (fr) 2020-10-28

Family

ID=58057136

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44227A MA44227B1 (fr) 2016-02-19 2017-02-17 Anticorps pour il-17c
MA43088A MA43088B1 (fr) 2016-02-19 2017-02-17 Anticorps anti-il-17c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44227A MA44227B1 (fr) 2016-02-19 2017-02-17 Anticorps pour il-17c

Country Status (33)

Country Link
US (5) US20190048071A1 (fr)
EP (1) EP3416983B1 (fr)
JP (2) JP6535139B2 (fr)
KR (1) KR102715157B1 (fr)
CN (1) CN108699143B (fr)
AU (1) AU2017219837B2 (fr)
BR (1) BR112018016798A2 (fr)
CA (1) CA3014842A1 (fr)
CL (1) CL2018002340A1 (fr)
CO (1) CO2018008724A2 (fr)
CU (1) CU20180087A7 (fr)
CY (1) CY1124296T1 (fr)
DK (1) DK3416983T3 (fr)
EA (1) EA037813B1 (fr)
EC (1) ECSP18070641A (fr)
ES (1) ES2877376T3 (fr)
HR (1) HRP20211059T1 (fr)
HU (1) HUE054755T2 (fr)
IL (1) IL260733B2 (fr)
LT (1) LT3416983T (fr)
MA (2) MA44227B1 (fr)
MD (1) MD3416983T2 (fr)
MX (1) MX2018009860A (fr)
PH (1) PH12018501739A1 (fr)
PL (1) PL3416983T3 (fr)
RS (1) RS62012B1 (fr)
SG (1) SG11201806161TA (fr)
SI (1) SI3416983T1 (fr)
SM (1) SMT202100361T1 (fr)
TN (1) TN2018000289A1 (fr)
TW (1) TW201734041A (fr)
WO (1) WO2017140831A1 (fr)
ZA (1) ZA201806249B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018529704A (ja) * 2015-10-05 2018-10-11 モルフォシス・アーゲー アトピー性皮膚炎の治療および／または予防のためのｉｌ−１７ｃの拮抗剤
SG11201806161TA (en) * 2016-02-19 2018-08-30 Morphosys Ag Antibodies for il-17c
EP3688031A1 (fr) * 2017-09-25 2020-08-05 MorphoSys AG Traitement de la dermatite atopique
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
EP4061825A1 (fr) * 2019-11-22 2022-09-28 MorphoSys AG Procédé pour augmenter le rendement d'anticorps pendant une chromatographie par échange d'ions
IL292940A (en) * 2019-11-22 2022-07-01 Morphosys Ag Collection of extractant during antibody chromatography

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (fr) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Sequences d'acides amines ayant une activite antigenique
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
AU740405B2 (en) * 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1990409A3 (fr) 1999-07-20 2011-05-18 MorphoSys AG Bactériophage
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
MX2007004597A (es) 2004-10-18 2007-06-22 Zymogenetics Inc Zcytor21 soluble, anticuerpos anti-zcytor21 y moleculas de enlace y metodos de uso en inflamacion.
CA2624763A1 (fr) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Antagonistes de il-17c et methodes d'utilisation desdits antagonistes
CA2666842A1 (fr) 2006-10-18 2008-04-24 Zymogenetics, Inc. Antagonistes de l'il-17c et leurs procedes d'utilisation
US20120201821A1 (en) * 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
HRP20181811T1 (hr) 2010-11-19 2018-12-28 Morphosys Ag Zbirka sljedova protutijela i njezina upotreba
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
SG11201401202YA (en) * 2011-10-19 2014-06-27 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
ES2685553T3 (es) 2012-06-12 2018-10-09 Orega Biotech Antagonistas de isoformas de IL-17 y sus usos
WO2016096896A1 (fr) * 2014-12-15 2016-06-23 Morphosys Ag Anticorps anti-il-17 c
SG11201806161TA (en) * 2016-02-19 2018-08-30 Morphosys Ag Antibodies for il-17c

Also Published As

Publication number Publication date
US10259869B2 (en) 2019-04-16
JP2019511910A (ja) 2019-05-09
US20200216529A1 (en) 2020-07-09
CU20180087A7 (es) 2019-03-04
MD3416983T2 (ro) 2021-08-31
CO2018008724A2 (es) 2018-08-31
PH12018501739A1 (en) 2019-06-10
PL3416983T3 (pl) 2021-10-25
EA201891594A1 (ru) 2019-01-31
ECSP18070641A (es) 2018-10-31
MA44227B1 (fr) 2021-06-30
US20180340024A1 (en) 2018-11-29
US20190048071A1 (en) 2019-02-14
CA3014842A1 (fr) 2017-08-24
CN108699143B (zh) 2021-11-09
US11987621B2 (en) 2024-05-21
CL2018002340A1 (es) 2018-11-23
US10633439B2 (en) 2020-04-28
IL260733B1 (en) 2023-11-01
HUE054755T2 (hu) 2021-09-28
MA43088B1 (fr) 2020-10-28
SMT202100361T1 (it) 2021-07-12
ZA201806249B (en) 2020-02-26
EA037813B1 (ru) 2021-05-24
CN108699143A (zh) 2018-10-23
TW201734041A (zh) 2017-10-01
TN2018000289A1 (en) 2020-01-16
AU2017219837A1 (en) 2018-08-09
US20190202906A1 (en) 2019-07-04
KR20180109977A (ko) 2018-10-08
HRP20211059T1 (hr) 2021-10-01
AU2017219837B2 (en) 2023-08-17
JP6916834B2 (ja) 2021-08-11
LT3416983T (lt) 2021-07-12
CY1124296T1 (el) 2022-11-25
WO2017140831A1 (fr) 2017-08-24
IL260733B2 (en) 2024-03-01
JP6535139B2 (ja) 2019-06-26
JP2019162119A (ja) 2019-09-26
ES2877376T3 (es) 2021-11-16
EP3416983A1 (fr) 2018-12-26
SG11201806161TA (en) 2018-08-30
MA44227A (fr) 2018-12-26
RS62012B1 (sr) 2021-07-30
KR102715157B1 (ko) 2024-10-10
SI3416983T1 (sl) 2021-08-31
MX2018009860A (es) 2019-03-28
DK3416983T3 (en) 2021-06-21
BR112018016798A2 (en) 2018-12-26
EP3416983B1 (fr) 2021-04-07
IL260733A (fr) 2018-09-20
US20250074978A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
MA43088B1 (fr) Anticorps anti-il-17c
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
WO2019224716A8 (fr) Anticorps spécifiques de gucy2c et leurs utilisations
SA521422581B1 (ar) أil-7r جسام مضادة للوحدة الثانوية ألفا واستخداماتها
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
MY191649A (en) Antibodies to tigit
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
TN2015000348A1 (en) Antibodies that bind il-23
WO2022051591A3 (fr) Anticorps anti-nectine-4 et leurs utilisations
EA202192101A1 (ru) Соединения и их применение
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
ZA201807816B (en) Anti-il-22r antibodies
WO2020089396A3 (fr) Compositions et procédés de traitement de maladies inflammatoires et auto-immunes
ZA202208280B (en) Antibody molecules to c5ar1 and uses thereof
MX2022001604A (es) Anticuerpos anti bdca-2.
ZA202006216B (en) Antibodies targeting glycoprotein vi
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MA43600A1 (fr) Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MA39559A1 (fr) Anticorps anti récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs utilisations
MA38302B1 (fr) Anticorps anti-pdgfr-bêta et leurs utilisations